Clinical trial · Interventional
Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
A Phase I/II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
NCT00572013CI-TRIAL-00069396completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the response rate, complete and partial, of patients with indolent lymphoma receiving Rituxan and BEAM with autologous stem cell transplant.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous stem cell transplant | Procedure | — | UNRESOLVED |
| BEAM | Drug | — | UNRESOLVED |
| Rituxan | Drug | Rituximab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm I Rituxan and BEAM post-autologous stem cell transplant
- description
- Rituxan and BEAM \[Carmustine (BCNU), Etoposide, Cytarabine (Ara-C, cytosine arabinoside), Melphalan\] will be a pre- and post-transplant agent to aid in the chemotherapy sensitization post-autologous stem cell transplant.
- interventionNames
- Drug: Rituxan
- Drug: BEAM
- Procedure: Autologous stem cell transplant
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 100 day
- description
- Disease response at day 100
Secondary outcomes (1)
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Any low-grade B-cell, CD20 positive, non-Hodgkin's lymphoma that is felt to otherwise be a transplant candidate (relapsed, induction failure, first PR or CR). o Small lymphocytic, marginal zone, mantle cell, and follicular histologies. * At least 19 years of age * Signed written informed consent * Expected survival of at least 6 months * WHO performance status greater or equal to 2 * Male or female subjects of reproductive potential who are able to follow accepted birth control measures. Exclusion Criteria: * No history of T-cell lymphoma * Not pregnant or lactating women * No serious disease or condition that, in the opinion of the investigator, would compromise the subject's ability to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.